1571 related articles for article (PubMed ID: 22027909)
21. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
[TBL] [Abstract][Full Text] [Related]
22. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.
Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588
[TBL] [Abstract][Full Text] [Related]
23. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
[TBL] [Abstract][Full Text] [Related]
24. [Role of 18F-FDG PET/CT in diagnosis and staging of nasopharyngeal carcinoma].
Lin XP; Zhao C; Chen MY; Fan W; Zhang X; Zhi SF; Liang PY
Ai Zheng; 2008 Sep; 27(9):974-8. PubMed ID: 18799039
[TBL] [Abstract][Full Text] [Related]
25. Detection of liver metastases in patients with adenocarcinomas of the gastrointestinal tract: comparison of (18)F-FDG PET/CT and MR imaging.
Maegerlein C; Fingerle AA; Souvatzoglou M; Rummeny EJ; Holzapfel K
Abdom Imaging; 2015 Jun; 40(5):1213-22. PubMed ID: 25348732
[TBL] [Abstract][Full Text] [Related]
26. (123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.
Cachin F; Miot-Noirault E; Gillet B; Isnardi V; Labeille B; Payoux P; Meyer N; Cammilleri S; Gaudy C; Razzouk-Cadet M; Lacour JP; Granel-Brocard F; Tychyj C; Benbouzid F; Grange JD; Baulieu F; Kelly A; Merlin C; Mestas D; Gachon F; Chezal JM; Degoul F; D'Incan M
J Nucl Med; 2014 Jan; 55(1):15-22. PubMed ID: 24263087
[TBL] [Abstract][Full Text] [Related]
27. Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging.
Beyer T; Pietrzyk U; Knoess C; Vollmar S; Wienhard K; Kracht L; Bockisch A; Maderwald S; Kühl H; Fitzek M
Nuklearmedizin; 2008; 47(2):73-9. PubMed ID: 18392316
[TBL] [Abstract][Full Text] [Related]
28. Minimal invasive biopsy of intraconal expansion by PET/CT/MRI image-guided navigation: a new method.
Reinbacher KE; Pau M; Wallner J; Zemann W; Klein A; Gstettner C; Aigner RM; Feichtinger M
J Craniomaxillofac Surg; 2014 Oct; 42(7):1184-9. PubMed ID: 24726395
[TBL] [Abstract][Full Text] [Related]
29. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
[TBL] [Abstract][Full Text] [Related]
30. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy.
Carnaghi C; Tronconi MC; Rimassa L; Tondulli L; Zuradelli M; Rodari M; Doci R; Luttmann F; Torzilli G; Rubello D; Al-Nahhas A; Santoro A; Chiti A
Nucl Med Rev Cent East Eur; 2007; 10(1):12-5. PubMed ID: 17694495
[TBL] [Abstract][Full Text] [Related]
31. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
32. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
[TBL] [Abstract][Full Text] [Related]
33. 18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.
Kirchner J; Sawicki LM; Deuschl C; Grüneisen J; Beiderwellen K; Lauenstein TC; Herrmann K; Forsting M; Heusch P; Umutlu L
PLoS One; 2017; 12(7):e0180349. PubMed ID: 28683109
[TBL] [Abstract][Full Text] [Related]
34. Does a novel penalized likelihood reconstruction of 18F-FDG PET-CT improve signal-to-background in colorectal liver metastases?
Parvizi N; Franklin JM; McGowan DR; Teoh EJ; Bradley KM; Gleeson FV
Eur J Radiol; 2015 Oct; 84(10):1873-8. PubMed ID: 26163992
[TBL] [Abstract][Full Text] [Related]
35. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
[TBL] [Abstract][Full Text] [Related]
36. Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease.
Denecke T; Steffen I; Hildebrandt B; Rühl R; Streitparth F; Lehmkuhl L; Langrehr J; Ricke J; Amthauer H; Hänninen EL
Acta Radiol; 2007 Oct; 48(8):821-30. PubMed ID: 17924212
[TBL] [Abstract][Full Text] [Related]
37. FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolisation therapy.
Schmidt GP; Paprottka P; Jakobs TF; Hoffmann RT; Baur-Melnyk A; Haug A; Notohamiprodjo M; Baur-Melnyk A; Nikolaou K; Reiser MF; Rist C
Eur J Radiol; 2012 Mar; 81(3):e269-76. PubMed ID: 21398060
[TBL] [Abstract][Full Text] [Related]
38. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
39. Improvement of hepatic lesion characterization by 18F-FDG PET/CT with the use of the lesion to background liver activity ratio.
Jolepalem P; Rydberg JN; Wong CO
Clin Nucl Med; 2013 Nov; 38(11):869-73. PubMed ID: 24089057
[TBL] [Abstract][Full Text] [Related]
40. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
